Bexil Corporation (BXLC)

Inozyme Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	1.88	3.12	3.15	-1.76	6.49	0.97
Depreciation & Amortization	-	-	0.36	0.36	0.36	0.36
Loss (Gain) From Sale of Investments	0.89	-0.45	-1.67	4.44	-4.3	2.63
Stock-Based Compensation	-	-	-	-	-	0
Other Operating Activities	-1.36	-1.29	-1.94	-0.31	-0.36	-1.74
Change in Accounts Receivable	0.03	-0.01	-0.02	0.05	0.13	-0.17
Change in Accounts Payable	0.25	0.03	0.04	-0.11	-0.03	0.04
Change in Other Net Operating Assets	0.16	-0.92	1.04	-0.01	-0.01	-0.05
Operating Cash Flow	1.58	0.44	1.73	1.98	2.21	0.48
Operating Cash Flow Growth	46.13%	-74.32%	-13.00%	-10.16%	363.09%	-37.77%
Investment in Securities	-	-	3.31	-3.25	-	2.5
Investing Cash Flow	-	-	3.31	-3.25	-	2.5
Issuance of Common Stock	0.12	0.12	0.12	0.12	0.49	0.12
Repurchase of Common Stock	-4.01	-4.01	-1.5	-0.03	-2.68	-0.19
Other Financing Activities	-	-	-	-	-0.04	-0.09
Financing Cash Flow	-3.89	-3.89	-1.38	0.09	-2.23	-0.16
Net Cash Flow	-2.31	-3.45	3.66	-1.17	-0.03	2.82
Cash Income Tax Paid	0.09	0.09	0.42	0.42	0.3	0.28
Levered Free Cash Flow	1.42	1.05	3.86	-1.1	4.64	-1.45
Unlevered Free Cash Flow	1.42	1.05	3.86	-1.1	4.64	-1.45

Source: S&P Global Market Intelligence. Standard template. Financial Sources.